glp-1 options TrimRX Comparing Ozempic, Wegovy and Other

2024 obesity Algorithm E-book: obesity medicine association

Eligible participants had CKD defined as either an eGFR of 5075 mL/min/1.73 m 2 with UACR 3005,000 mg/g, or an eGFR of 25 to 50% eGFR decline, ESKD, or all-cause mortality [81]

Levels Take: Ultimately, GLP1 medications are not a sustainable solution to obesity or poor metabolic health for the vast majority of people

While more research is ongoing, early findings show it may suppress appetite more aggressively than semaglutide, making it a powerful option for some

Phase 3 Update: TRIUMPH-4 Results Preliminary data from the ongoing Phase 3 TRIUMPH-4 trial (68 weeks) shows higher numbers than Phase 2: 12mg dose: 28.7% average weight loss (~71 lbs / 32 kg) 9mg dose: 26.4% average weight loss (~64 lbs / 29 kg) Knee osteoarthritis pain: 76% reduction (significant quality-of-life improvement) Blood pressure: Average reduction of 14 mmHg Full Phase 3 results across the TRIUMPH program (obesity, diabetes, cardiovascular outcomes, kidney outcomes) are expected throughout 2026

Economic Implications on Healthcare: The extensive use of GLP-1 drugs might assist in lowering the burden on the healthcare system by potentially reducing the number of complications and comorbidities related to obesity and diabetes, such as heart diseases, kidney issues, and stroke